AMGN
Amgen Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +0.2% · net new positions -3.8% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 171 | -1 | 369.41M | $133.69B | +5 | −5 |
| Q1 2026 | 174 | -2 | 366.40M | $128.82B | +4 | −7 |
| Q4 2025 | 175 | 0 | 394.29M | $128.98B | +2 | −1 |
| Q3 2025 | 26 | 0 | 206.42M | $58.23B | — | −1 |
| Q2 2025 | 24 | +1 | 183.25M | $51.15B | +2 | −1 |
| Q1 2025 | 20 | -2 | 81.79M | $25.47B | — | −2 |
| Q4 2024 | 22 | +2 | 74.78M | $19.48B | +2 | — |
| Q3 2024 | 19 | -1 | 39.65M | $12.76B | +1 | −2 |
| Q2 2024 | 20 | — | 39.58M | $12.36B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 53.88M | +0.3% | $15.20B | 0.2% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 46.03M | -1.2% | $12.99B | 0.2% | ▼ Trim | 2 | SEC ↗ ×24 |
| 3 | State Street Global Advisors ✦ (passive) | 29.30M | -0.2% | $8.27B | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 4 | Capital World Investors ✦ | 18.80M | +11.5% | $5.30B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 5 | Morgan Stanley ✦ | 15.91M | — | $4.49B | 0.3% | n/c | 1 | SEC ↗ ×21 |
| 6 | Geode Capital Management ✦ (passive) | 13.27M | +1.9% | $3.73B | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 9.71M | -8.7% | $2.74B | 2.1% | ▼ Trim | 6 | SEC ↗ |
| 8 | JPMorgan Chase ✦ | 8.46M | — | $2.39B | 0.1% | n/c | 1 | SEC ↗ ×38 |
| 9 | Goldman Sachs Group ✦ | 4.45M | — | $1.25B | 0.2% | n/c | 1 | SEC ↗ ×5 |
| 10 | Fidelity (FMR) ✦ | 3.40M | -7.2% | $960.63M | 0.1% | ▼ Trim | 2 | SEC ↗ ×5 |
| 11 | T. Rowe Price ✦ | 1.06M | -7.6% | $297.88M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Fisher Asset Management ✦ | 785.28K | +91.6% | $221.61M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 237.69K | +25.9% | $67.08M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 205.78K | -23.6% | $57.24M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 15 | Renaissance Technologies ✦ | 167.25K | -39.7% | $47.20M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 150.85K | +418.1% | $42.57M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | Millennium Management ✦ | 144.93K | +325.3% | $40.90M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 128.86K | -79.4% | $36.36M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 19 | Wellington Management ✦ | 96.96K | -32.4% | $27.36M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 20 | Two Sigma Investments ✦ | 76.42K | +2256.6% | $21.57M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Arrowstreet Capital ✦ | 62.53K | -70.8% | $17.65M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 22 | ARK Investment Management ✦ | 47.27K | -18.4% | $13.34M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 23 | Gotham Asset Management ✦ | 20.49K | -12.1% | $5.78M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 24 | Dodge & Cox ✦ | 13.37K | -2.3% | $3.77M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 25 | Bridgewater Associates ✦ | 11.29K | +51.9% | $3.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 26 | GAMCO Investors ✦ | 5.14K | -9.6% | $1.45M | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $1.66B | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3,100 holders, 420.54M shares, $144.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.25K sh · $521,365
Officer · 2.00K sh · $825,134
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology